Arna Pharma Inc. and Slate Run Pharmaceuticals Finalize Joint Venture and Launch First Brand Product

Arna Pharma Inc. and Slate Run Pharmaceuticals have officially finalized their joint venture, creating a specialized U.S.-based pharmaceutical company. This partnership aims to focus on branded products, 505(b)(2) medicines, and specialized generics, leveraging Arna Pharma’s development capabilities and Slate Run’s commercial infrastructure. They have also launched their first brand product, Aridol®, with plans for additional products in the future, seeking to expand market presence in high-value therapeutic segments.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pinned